Podcasts about therapies

Send us Fan MailIn this Journal Club episode, Daphna reviews the first national estimate of potential neonatal organ donors, a Pediatrics cohort study from 23 Australian NICUs, along with its companion commentary. Of 1,760 infants who died in the NICU between 2012 and 2022 at 35 weeks corrected age or later, about one in three met conservative eligibility criteria. Most would have donated after circulatory death, and a smaller group with severe HIE could potentially have donated after neurological determination of death. They discuss referral timing, outcomes of en bloc kidney transplants from neonatal donors, and how NICUs can offer families this option as part of end-of-life care.----Potential Neonatal Donors in Australia: A National Cohort Study. Barzegar R, Cavazzoni E, Popat H, Wong G.Pediatrics. 2026 Sep 3:e2025075110. doi: 10.1542/peds.2025-075110. Online ahead of print.PMID: 42686207The Untapped Potential of Organ Donation from the NICU. Nguyen BV, Coloma M, Crouch EE.Pediatrics. 2026 Sep 3:e2026076954. doi: 10.1542/peds.2026-076954. Online ahead of print.PMID: 42686210 No abstract available.Support the showAs always, feel free to send us questions, comments, or suggestions to our email: nicupodcast@gmail.com. You can also contact the show through Instagram or Twitter, @nicupodcast. Or contact Ben and Daphna directly via their Twitter profiles: @drnicu and @doctordaphnamd. The papers discussed in today's episode are listed and timestamped on the webpage linked below.Enjoy!

Dr. Diane and Sue Martovich owner of Salt of the Earth in Woodbury, CT discuss developing your inner guidance and intuition to heal autoimmune disease, cancer, respiratory disease and more. They discuss advanced technologies for energy healing and how frequency medicine and vibrational medicine are the wave of the future. 

Send us Fan MailIn this Journal Club episode, Ben reviews a JAMA Network Open study from two Dutch Level IV NICUs. It examined NEC before and after routine implementation of a three-strain probiotic in 1,413 infants born before 30 weeks or under 1,000 grams. NEC fell from 11.9% to 5.3%, and late-onset sepsis also declined. But non-NEC mortality rose after implementation. NEC also dropped in an unexposed reference cohort, and one infant died of B. infantis sepsis. Ben and Daphna discuss how baseline NEC rates, seasonal patterns, and number needed to harm should shape how units weigh probiotic use.----Probiotic Implementation and Necrotizing Enterocolitis Risk in Preterm Infants. Imren C, Jongejans V, Onland W, Keyzer-Dekker CMG, Been JV, Derikx JPM, van Kaam AH, Simons SHP, Twisk JWR, van den Akker CHP, Vermeulen MJ.JAMA Netw Open. 2026 Aug 3;9(8):e2631601. doi: 10.1001/jamanetworkopen.2026.31601.PMID: 42671836 Free PMC article.Support the showAs always, feel free to send us questions, comments, or suggestions to our email: nicupodcast@gmail.com. You can also contact the show through Instagram or Twitter, @nicupodcast. Or contact Ben and Daphna directly via their Twitter profiles: @drnicu and @doctordaphnamd. The papers discussed in today's episode are listed and timestamped on the webpage linked below.Enjoy!

Welcome to the Oncology Brothers podcast! In this episode, we dived into the latest advancements in HER2-targeted therapies for upper gastrointestinal malignancies, with Drs. Shruti Patel and Samuel Cytryn.   Join us as we discussed: The recent approval of zanidatamab and its implications for HER2-positive esophageal and gastric adenocarcinoma The role of trastuzumab in treatment and its associated side effects, including cardiotoxicity and infusion reactions Addressing different dose used for trastuzumab deruxtecan (T-DXd) in upper GI space, along with important side effect profile to keep in mind The importance of shared decision-making in treatment options and the impact of dosing strategies on patient outcomes   We also covered the critical need for biomarker-driven treatment approaches, including HER2 status and PD-L1 scores, and how these factors influence therapy choices.   Listen us on: Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o  Follow us on social media:  ⁠X/Twitter: https://x.com/oncbrothers  ⁠Instagram: https://www.instagram.com/oncbrothers  Website: https://oncbrothers.com/    Tune in for an informative discussion that bridges the gap between research and clinical practice, ensuring that patients receive the best care possible. Don't forget to like, subscribe, and hit the notification bell for more episodes! #HER2positive, #UpperGICancer, #Zanidatamab, #Trastuzumab, #TDXd, #OncologyBrothers

In this episode, produced in coordination with Oncology Nursing News®, Beth Faiman, PhD, MSN, APN-BC, AOCN, FAAN, FAPO, and Sikander Ailawadhi, MD, discussed evolving administration strategies for multiple myeloma therapies, primarily focusing on subcutaneous and on-body administration. Dr Faiman is an adult nurse practitioner in the Department of Hematology/Oncology at the Cleveland Clinic and a clinical member of the Cancer Prevention, Control and Population Research Program at Case Comprehensive Cancer Center in Ohio. Dr Ailawadhi is a consultant in the Division of Hematology/Oncology in the Department of Internal Medicine, a consultant in the Department of Cancer Biology, and a professor of medicine at Mayo Clinic in Rochester, Minnesota.In the first episode of a 3-part series, Drs Faiman and Ailawadhi outlined the transition to subcutaneous administration of anti-CD38 monoclonal antibodies in multiple myeloma management. They also highlighted the significance of the July 2026 FDA approval of satuximab-irfc (Sarclisa Escena) for subcutaneous injection for multiple myeloma indications, which includes administration with the CirCLIQ on-body delivery system. 

Highlights from the PER® CME activity "OncoBytes Adaptive Learning Pathways™: Decoding Precision Diagnostics and Targeted Therapies in Glioma" — this podcast is not certified for credit. To participate in the full accredited activity and earn CME credit, use the link below.In this podcast, experts Vinay K. Puduvalli, MD; Ruham Nasany, MD; and Angela Waanders, MD, MPH, MS; discuss advances in molecular diagnostics and strategies to treat adults with low- and high-grade gliomas.Earn CME credit by completing the full accredited activity (available through September 1, 2027): https://www.gotoper.com/courses/oncobytes-adaptive-learning-pathways-decoding-precision-diagnostics-and-targeted-therapies-in-gliomaThis podcast, including the narration, was developed by PER® (Physicians' Education Resource®, LLC) editorial staff from the full online CME activity developed with these faculty. The narration was voiced by a PER staff member or by an AI tool. The podcast contains no product advertising. The full activity is supported by an educational grant from Jazz Pharmaceuticals, Inc.This content is for educational purposes only and is not a substitute for the independent clinical judgment of a health care professional. Faculty may discuss investigational or off-label uses; consult prescribing information for any products discussed.

The future of healing may be closer than you think. The next breakthrough in healing may not come from a new drug—but from frequencies, light, and energy. Michael Upstone has spent nearly twenty years studying regenerative technologies such as frequencies, soft lasers, hydrogen therapy, and much more. Hear the science, the remarkable case studies, and why this field is capturing growing interest around the world!

In this episode of Living Well with MS -- where we explore topics relating to living a full and healthy life with multiple sclerosis -- we are pleased to welcome Brett Drummond and Karen Campbell. Brett is from MSTranslate and hosts the European Committee for Treatment and Research In Multiple Sclerosis (ECTRIMS) patient day and podcast. Karen is a nurse and MS researcher who lives with MS and attended the conference this year. Watch this episode on YouTube. Keep reading for the topics, timestamps, and our guest's bio. 00:00 Introduction to ECTRIMS 2025 and Speakers 02:02 Overview of ECTRIMS Conference Highlights 02:41 Brett's Insights on MS Research 09:07 Emerging Treatments and Therapies for MS 15:10 The Role of Viruses in MS 18:28 Lifestyle Modifications and Rehabilitation in MS 20:03 Biomarkers and Their Importance in MS 24:24 Engaging the MS Community in Research 28:24 Karen's Perspective as a Patient and Researcher 33:55 Q&A Session: Addressing Community Questions Watch the original presentation here Connect with Ciara on LinkedIn New to Overcoming MS? Learn why lifestyle matters in MS - begin your journey at our 'Get started' page Connect with others following Overcoming MS on the Live Well Hub Visit the Overcoming MS website Follow us on social media: Facebook Instagram YouTube Pinterest Don't miss out: Subscribe to this podcast and never miss an episode. Listen to our archive of Living Well with MS here. Make sure you sign up to our newsletter to hear our latest tips and news about living a full and happy life with MS. Support us: If you enjoy this podcast and want to help us continue creating future podcasts, please leave a donation here. Feel free to share your comments and suggestions for future guests and episode topics by emailing podcast@overcomingms.org. If you like Living Well with MS, please leave a 5-star review.

Listen to Jesus G. Berdeja, MD, and Ajai Chari, MD, as they discuss sequencing of antibody–drug conjugates (ADCs), bispecific antibodies, CAR T-cell therapy, and other novel treatment modalities for patients with relapsed/refractory multiple myeloma.Presenters:Jesus G. Berdeja, MDDirector of Myeloma ResearchGreco-Hainsworth Centers for Research PartnerTennessee OncologyNashville, TennesseeAjai Chari, MDProfessor of Clinical MedicineDirector of Multiple Myeloma ProgramUCSF Helen Diller Family Comprehensive Cancer CenterUniversity of California, San Francisco (UCSF) Medical CenterSan Francisco, CaliforniaContent based on an online CME program supported by an educational grant from GSK.Link to full program:https://bit.ly/3TZSmufGet access to all of our new podcasts by subscribing to the Decera Clinical Education Oncology Podcast on Apple Podcasts, YouTube Music, or Spotify. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Send us Fan MailIn this Journal Club episode, Daphna presents a JAMA Pediatrics randomized trial led by Mandy Belfort and Terrie Inder. It tested whether point-of-care human milk analysis, used to individually target protein and fat fortification, improves outcomes in infants born at 24 to 30 weeks. Milk was analyzed every weekday with the Miris analyzer. Fortification in the intervention group was adjusted to meet protein and energy targets. Growth, body composition by air displacement plethysmography, and term-equivalent brain MRI were no different from standard fortification, and all infants met recommended intakes. Two-year outcomes will be reported separately.----Individually Targeted Human Milk Fortification: A Randomized Clinical Trial. Belfort MB, Ahtam B, Bell KA, Berger P, Cherkerzian S, Ellard D, Foster L, Fusch C, Gagoski B, Grant PE, Kuncham M, Pepin H, Solti M, Steele T, Woodward L, Inder T.JAMA Pediatr. 2026 Sep 14:e264220. doi: 10.1001/jamapediatrics.2026.4220. Online ahead of print.PMID: 42734908Support the showAs always, feel free to send us questions, comments, or suggestions to our email: nicupodcast@gmail.com. You can also contact the show through Instagram or Twitter, @nicupodcast. Or contact Ben and Daphna directly via their Twitter profiles: @drnicu and @doctordaphnamd. The papers discussed in today's episode are listed and timestamped on the webpage linked below.Enjoy!

Discover how novel APRIL and dual BAFF/APRIL inhibitors directly interrupt IgA nephropathy pathogenesis. Credit available for this activity expires: 9/29/27 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/targeting-source-dissecting-mechanisms-emerging-b-cell-2026a1000zi7?ecd=bdc_podcast_libsyn_mscpedu

Send us Fan MailIn this Journal Club episode, Ben and Daphna review the 24-month follow-up of the BeNeDuctus trial, which compared expectant management with early ibuprofen for PDA in infants born before 28 weeks. Survival without neurodevelopmental impairment was identical in both groups, at 49%. Ben places the findings alongside Baby-OSCAR, the PDA trial, TRIOCAPI, and SMART-PDA, and explains why a neutral result does not mean no PDA should ever be treated. The conversation then turns to how targeted neonatal echocardiography and lung ultrasound are changing bedside PDA assessment, and previews an upcoming hemodynamics series with Dr. Gabriel Altit.----Long-Term Outcomes of Expectant Management versus Early Ibuprofen for Patent Ductus Arteriosus: 24-Month Follow-Up of the BeNeDuctus Trial. Apers WMJ, Hundscheid T, Kooi EMW, Onland W, Vijlbrief D, Steiner K, Donders R, Mulder AL, de Boode WP; BeNeDuctus Trial Investigators.J Pediatr. 2026 Sep 17;299:115292. doi: 10.1016/j.jpeds.2026.115292. Online ahead of print.PMID: 42637114 Support the showAs always, feel free to send us questions, comments, or suggestions to our email: nicupodcast@gmail.com. You can also contact the show through Instagram or Twitter, @nicupodcast. Or contact Ben and Daphna directly via their Twitter profiles: @drnicu and @doctordaphnamd. The papers discussed in today's episode are listed and timestamped on the webpage linked below.Enjoy!

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Krina Patel, MD, MSc As CAR T-cell therapy options expand for relapsed or refractory (R/R) multiple myeloma, comparative data may help clinicians weigh efficacy and safety when selecting treatment. One recent matching-adjusted indirect comparison of anitocabtagene autoleucel and ciltacabtagene autoleucel drew on data from the iMMAGINE-1 and CARTITUDE-1 trials to evaluate response and safety outcomes, including cytokine release syndrome, ICANS, infections, and non-relapse mortality. To learn about the findings, their clinical implications, and important limitations of the analysis, Dr. Charles Turck speaks with Dr. Krina Patel, Professor in the Department of Lymphoma and Myeloma at the University of Texas MD Anderson Cancer Center in Houston. She also presented these data at the 2026 International Myeloma Society Annual Meeting.

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Krina Patel, MD, MSc A recent analysis used matching-adjusted indirect comparisons to evaluate anitocabtagene autoleucel, teclistamab, and talquetamab for relapsed or refractory (R/R) multiple myeloma, drawing on data from the iMMAGINE-1, MajesTEC-1, and MonumenTAL-1 trials. The analysis compared efficacy and safety outcomes across these CAR T-cell and bispecific therapies, including overall response, depth of response, MRD negativity, cytokine release syndrome, ICANS, infections, and non-relapse mortality. To explore the findings, their potential clinical implications, and key limitations of these indirect comparisons, Dr. Charles Turck speaks with Dr. Krina Patel, Professor in the Department of Lymphoma and Myeloma at the University of Texas MD Anderson Cancer Center in Houston. She also presented these data at the 2026 International Myeloma Society Annual Meeting.

Send us Fan MailFeeding in the NICU is rarely one person's job, yet the language around it changes from nurse to therapist to physician to parent. In this Tech Tuesday episode, Ben and Daphna sit down with Lisa Kleinz and Erin Lesage of Dr. Brown's Medical to unpack feeding together, a philosophy built on team approach, family at the center, and feeding that begins on day one rather than at first bottle. They discuss what separates cue-based feeding from a truly standardized Infant-Driven Feeding® Program, the outcomes reported so far, and why nearly half of NICU graduates still struggle with feeding at home. A practical conversation about culture, consistency, and shared language.https://www.drbrownsmedical.com/infant-driven-feeding-program/infant-driven-feeding-program-about/Support the showAs always, feel free to send us questions, comments, or suggestions to our email: nicupodcast@gmail.com. You can also contact the show through Instagram or Twitter, @nicupodcast. Or contact Ben and Daphna directly via their Twitter profiles: @drnicu and @doctordaphnamd. The papers discussed in today's episode are listed and timestamped on the webpage linked below.Enjoy!

In this episode of the Lupus Foundation of America's The Expert Series podcast, we focus on GLP-1 Therapies and Lupus. Our guest, Dr. Paul Hoover, discusses what we know about obesity and its impact on people living with lupus, how GLP-1 therapies work, and what researchers are learning about their potential role in lupus and related health outcomes.Sign up to receive emails from the Lupus Foundation of America (LFA) when new episodes are published: https://support.lupus.org/site/SPageNavigator/email_subscribe_expert_series.htmlEpisode Takeaways:Why obesity is an important consideration for people living with lupusWhat we currently understand about the relationship between obesity and lupus outcomesHow GLP-1 therapies work and why researchers are interested in their potential role in lupusWhat is known—and what remains unknown—about the potential effects of GLP-1 therapies beyond weight loss, including blood sugar and kidney healthWhat people living with lupus should know when considering GLP-1 therapies and discussing them with their healthcare teamRelated Resources:Ask a Lupus Health Educator (LFA): https://www.lupus.org/care-support/ask-a-health-educatorFind Support Near You (LFA): https://www.lupus.org/resources/find-support-near-youNational Resource Center on Lupus (LFA): https://www.lupus.org/resourcesThe Expert Series (LFA): https://www.lupus.org/resources/lupus-the-expert-seriesResearch Accelerated by You (LFA): https://www.lupus.org/research/enroll-in-a-lupus-registry

For people with ultra-rare genetic diseases, a diagnosis can come with a devastating realization that there may be no treatment in development because the patient population is too small to attract traditional biopharma investment. Nome is working to change that by combining patient-led drug development with AI-enabled scientific and operational support. Steven Ringel, founder and CEO of Nome and founder of the Kizuna Foundation, discusses how the company is helping families and patient organizations identify viable genetic-medicine options, build development plans, and find qualified partners who can help advance individualized therapies toward the clinic.

In this episode of the Medical Sales Podcast, Samuel Adeyinka sits down with Pete Okonkwo, a Vascular Therapies Consultant at Boston Scientific, to give listeners an inside look at what it really takes to succeed in vascular medical device sales. Pete explains what a typical day looks like, from arriving early for procedures and managing inventory to supporting interventional radiologists, interventional cardiologists, and vascular surgeons in the cath lab and hybrid OR. He breaks down the differences between vascular therapies and his previous experience as a Surgical Account Manager, including the complexity of vascular procedures, the importance of understanding imaging and anatomy, and why reps must be able to adapt quickly as cases change. Pete also shares what it takes to manage multiple accounts, balance case coverage with business development, and build strong relationships with surgeons while maintaining emotional intelligence and situational awareness in the operating room. He discusses the importance of being a self-starter, managing your own time, staying several steps ahead during procedures, and knowing when to speak up and when to simply support the surgeon. Most importantly, Pete shares a powerful story from one of his early experiences in vascular therapies that showed him the real impact medical sales can have on patient care. Whether you're considering a career in vascular therapies, trying to understand what medical device reps actually do, or looking to become a stronger sales professional in the OR, this episode offers an honest look at the skills, mindset, and clinical knowledge required to succeed. Connect with Pete Okonkwo: LinkedIn Connect with Me: LinkedIn Love the show? Subscribe, rate, review, and share! Here's How »

Professor Robin Ali, Director of the Centre for Gene Therapy & Regenerative Medicine, KCL.

Can CAR T-cell therapies achieve drug-free remission in severe refractory autoimmune diseases? Credit available for this activity expires: 9/22/27 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/patient-journey-severe-refractory-autoimmune-rheumatic-2026a1000xbu?ecd=bdc_podcast_libsyn_mscpedu

The Lymphoma Hub was pleased to speak to Nirav Shah, Medical College of Wisconsin, Milwaukee, US. We asked, What is the current clinical evidence for tandem chimeric antigen receptor (CAR) T-cell therapies in relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL)? This educational resource is independently supported by Miltenyi Biomedicine. All content is developed by SES in collaboration with an expert steering committee. Funders are allowed no influence. Hosted on Acast. See acast.com/privacy for more information.

Send us Fan MailBen sits down with Dr. Shetal Shah and AAP federal advocacy director Stephanie Glier to unpack HR1, the sweeping reconciliation bill that could cut $1.15 trillion in federal Medicaid spending over the next decade. With 40% of US births and up to 65% of NICU graduates covered by Medicaid, the stakes for neonatology are enormous. Shetal and Stephanie break down state directed payments, provider taxes, shortened retroactive coverage windows, and new work requirements, explaining how administrative friction alone could push families out of coverage. They also offer a clear playbook: connect with your AAP state chapter, share bedside stories with policymakers, and don't be more intimidated by a congressional office than by a resuscitation.----AAP Advocacy page: https://www.aap.org/en/advocacy/?srsltid=AfmBOoqcnlKDsPZkpNg6z6U7OlOuBqUiuCtWHrUPmRGzfqDiQEl-vf7sMyers CN, Beck AF. H.R. 1's Medicaid cuts threaten children's health. Health Affairs Forefront. January 20, 2026. Accessed August 28, 2026. https://www.healthaffairs.org/content/forefront/h-r-1-s-medicaid-cuts-threaten-children-s-healthLittle J, Kohler A. How H.R. 1 cuts and changes to Medicaid played out in 2026 state legislative sessions (Part 2). Georgetown University Center for Children and Families. July 2, 2026. Accessed August 28, 2026. https://ccf.georgetown.edu/2026/07/02/how-h-r-1-cuts-and-changes-to-medicaid-played-out-in-2026-state-legislative-sessions-part-2/Academy of Managed Care Pharmacy. Implications of H.R. 1 – the One Big Beautiful Bill Act. Academy of Managed Care Pharmacy. 2026. Accessed August 28, 2026. https://www.amcp.org/H.R.1Park E. New CMS guidance on H.R. 1's restrictions of state directed payments. Georgetown University Center for Children and Families. February 4, 2026. Accessed August 28, 2026. https://ccf.georgetown.edu/2026/02/04/new-cms-guidance-on-h-r-1s-restrictions-of-state-directed-payments/Mudumala A, Mohamed M, Tolbert J, Burns A. The impact of H.R. 1 on two Medicaid eligibility rules. KFF. September 22, 2025. Accessed August 28, 2026. https://www.kff.org/medicaid/the-impact-of-h-r-1-on-two-medicaid-eligibility-rules/ Support the showAs always, feel free to send us questions, comments, or suggestions to our email: nicupodcast@gmail.com. You can also contact the show through Instagram or Twitter, @nicupodcast. Or contact Ben and Daphna directly via their Twitter profiles: @drnicu and @doctordaphnamd. The papers discussed in today's episode are listed and timestamped on the webpage linked below.Enjoy!

The promise of cell and gene therapies is big. They have the ability to address the underlying genetic causes of...[…]

The promise of cell and gene therapies is big. They have the ability to address the underlying genetic causes of...

Send us Fan MailThis week on The Incubator Podcast, Ben and Daphna dig into four studies reshaping bedside decisions. They open questioning whether routine DAT screening for ABO and RhD incompatibility still earns its place, finding transcutaneous bilirubin alone predicts phototherapy need just as well. Next, a Swedish national registry of over two million births links missed intramuscular vitamin K, and rising oral substitution, to a near-doubling of bleeding and intracranial hemorrhage risk. Ben then presents the PHILODENDRON pilot trial out of Milan, testing initial delivery-room CPAP of 5 versus 8 cmH2O in infants under 30 weeks, feasible and safe, but not yet enough to settle the physiology question. Daphna closes Journal Club with a SART-linked study tying IVF conception to significantly higher odds of VACTERL association. The week wraps with Ben and Eli on Neo News, unpacking a study showing birth certificates miss nearly 40% of true NICU admissions, with troubling racial disparities.----Utility of DAT in Low-Risk Neonates With ABO or RhD Incompatibility. Tsai TL, Ma T, Nester T.Pediatrics. 2026 Sep 1;158(3):e2026076989. doi: 10.1542/peds.2026-076989.PMID: 42642037Vitamin K Prophylaxis in Newborns and Bleeding in Infancy. Simatou E, Tsamantioti E, Hallström A, Stephansson O, Razaz N, Persson M, Bolk J.JAMA Pediatr. 2026 Sep 1;180(9):995-1004. doi: 10.1001/jamapediatrics.2026.2606.PMID: 42440325Initial CPAP of 5 versus 8 cmH2O during delivery room stabilisation of very preterm infants: the PHILODENDROOM pilot randomised trial. Cavigioli F, Bresesti I, Castoldi F, Gatto S, Lupo E, Rossi S, La Verde A, Bianchi S, Meneghin F, Viaroli F, Pivetti V, Manfredini V, Cannata G, Bastrenta P, Fontana P, Stucchi I, Daniele I, Chiera M, Lista G.Eur J Pediatr. 2026 Aug 17;185(9):673. doi: 10.1007/s00431-026-07322-6.PMID: 42608615 Free PMC article. Clinical Trial.In Vitro Fertilization and VACTERL Birth Defects. Tark JY, Richard MA, Schraw JM, Fisher SC, Betancourt D, Stone SL, Forestieri NE, Baker VL, Cameron K, Eisenberg ML, Belva F, Lu Y, Williams CL, Sutcliffe AG, Lupo PJ, Luke B.JAMA Netw Open. 2026 Aug 3;9(8):e2629355. doi: 10.1001/jamanetworkopen.2026.29355.PMID: 42616500 Free PMC article.Birth certificate data substantially misrepresent actual NICU admissions, including among most vulnerable. Hughes CS, Lorch SA, Schmitt S, Passarella M, Phibbs CS.J Perinatol. 2026 Jul;46(7):1307-1312. doi: 10.1038/s41372-026-02726-6. Epub 2026 May 27.PMID: 42204354Support the showAs always, feel free to send us questions, comments, or suggestions to our email: nicupodcast@gmail.com. You can also contact the show through Instagram or Twitter, @nicupodcast. Or contact Ben and Daphna directly via their Twitter profiles: @drnicu and @doctordaphnamd. The papers discussed in today's episode are listed and timestamped on the webpage linked below.Enjoy!

Send us Fan MailBen and Eli dig into a Journal of Perinatology study that asks a deceptively simple question: can we trust birth certificate data to tell us how many babies actually need NICU care? The answer, it turns out, is no. Nearly 40% of NICU admissions are missing from birth certificates, with the biggest gaps among full-term and late-preterm infants, and troubling racial disparities in which admissions get missed. Ben and Eli unpack what this means for how states and hospitals allocate resources, why underreporting could be quietly starving NICUs of funding and attention, and why pairing solid epidemiologic data with individual bedside stories may be the most effective way to make the case for better-resourced newborn care.----Birth certificate data substantially misrepresent actual NICU admissions, including among most vulnerable. Hughes CS, Lorch SA, Schmitt S, Passarella M, Phibbs CS.J Perinatol. 2026 Jul;46(7):1307-1312. doi: 10.1038/s41372-026-02726-6. Epub 2026 May 27.PMID: 42204354Support the showAs always, feel free to send us questions, comments, or suggestions to our email: nicupodcast@gmail.com. You can also contact the show through Instagram or Twitter, @nicupodcast. Or contact Ben and Daphna directly via their Twitter profiles: @drnicu and @doctordaphnamd. The papers discussed in today's episode are listed and timestamped on the webpage linked below.Enjoy!

Send us Fan MailBen and Daphna  dig into a large, population-based study linking IVF conception to VACTERL association, a rare but serious pattern of congenital anomalies spanning the vertebral, anal, cardiac, tracheoesophageal, renal, and limb systems. Drawing on over 1.5 million births across four US states and linked SART registry data, the study finds IVF-conceived infants face significantly higher odds of VACTERL and related multiple anomaly syndromes compared to naturally conceived infants. Daphna and Ben unpack what this means for clinical suspicion at the bedside, why some VACTERL phenotypes may be easy to miss, and how better tracking of conception history through delivery could change how NICU teams approach anomaly workups in IVF-conceived infants.----In Vitro Fertilization and VACTERL Birth Defects. Tark JY, Richard MA, Schraw JM, Fisher SC, Betancourt D, Stone SL, Forestieri NE, Baker VL, Cameron K, Eisenberg ML, Belva F, Lu Y, Williams CL, Sutcliffe AG, Lupo PJ, Luke B.JAMA Netw Open. 2026 Aug 3;9(8):e2629355. doi: 10.1001/jamanetworkopen.2026.29355.PMID: 42616500 Free PMC article.Support the showAs always, feel free to send us questions, comments, or suggestions to our email: nicupodcast@gmail.com. You can also contact the show through Instagram or Twitter, @nicupodcast. Or contact Ben and Daphna directly via their Twitter profiles: @drnicu and @doctordaphnamd. The papers discussed in today's episode are listed and timestamped on the webpage linked below.Enjoy!

Send us Fan MailBen and Daphna dig into a pilot RCT that asks a deceptively simple delivery-room question: should very preterm infants start on CPAP of 5 or CPAP of 8 cmH2O? The PHILODENDRON trial, out of Milan's Buzzi Children's Hospital, randomized 56 babies born between 26 and 29 weeks to find out — testing feasibility, safety, and early physiological adaptation before committing to a larger multicenter trial. No major safety signals emerged, but babies on lower CPAP reached surfactant thresholds faster, while higher CPAP trended toward fewer air leaks and shorter ventilation. Ben and Daphna weigh the physiology against the data, and ask whether trials like this even test the right question in the first place.----Initial CPAP of 5 versus 8 cmH2O during delivery room stabilisation of very preterm infants: the PHILODENDROOM pilot randomised trial. Cavigioli F, Bresesti I, Castoldi F, Gatto S, Lupo E, Rossi S, La Verde A, Bianchi S, Meneghin F, Viaroli F, Pivetti V, Manfredini V, Cannata G, Bastrenta P, Fontana P, Stucchi I, Daniele I, Chiera M, Lista G.Eur J Pediatr. 2026 Aug 17;185(9):673. doi: 10.1007/s00431-026-07322-6.PMID: 42608615 Free PMC article. Clinical Trial.Support the showAs always, feel free to send us questions, comments, or suggestions to our email: nicupodcast@gmail.com. You can also contact the show through Instagram or Twitter, @nicupodcast. Or contact Ben and Daphna directly via their Twitter profiles: @drnicu and @doctordaphnamd. The papers discussed in today's episode are listed and timestamped on the webpage linked below.Enjoy!

Today Parkinson's treatments are largely focused on helping manage symptoms, but researchers are working towards something more: treatments that address a wider range of symptoms and ultimately slow or stop disease progression. Getting there will likely take many different approaches, reflecting the many ways Parkinson's can affect people.In this episode of the MJFF Parkinson's Podcast, part of its award-winning Parkinson's Science POV series, host Maggie Kuhl, vice president of patient engagement at MJFF, leads a conversation with MJFF Chief Scientific Officers Brian Fiske, PhD and Mark Frasier, PhD, about how researchers are building a more diverse pipeline of potential treatments. They discuss how learning more about Parkinson's are opening doors to new approaches, and the importance of centering what really matters for people living with the disease.Maggie also speaks with Shalini Padmanabhan, PhD, MJFF's head of translational research, about the Foundation's Targets to Therapies program and how MJFF is helping discoveries move closer to new treatments.Mentioned in this episode:All Grit. No Quit. is our bold Campaign to raise $2.5 billion by 2028. This is our biggest push yet toward a world without Parkinson's and we need to bring the full force of our community to meet this moment. Whatever brings you here, you can be a part of accelerating what comes next. michaeljfox.org/campaign/all-grit-no-quit

The FDA held a public forum on Monday to discuss the future of psychedelic therapeutics, followed by a meeting on Wednesday regarding recommendations for reauthorizing the Prescription Drug User Fee Act the day after launching its TrialBlazer initiative. Meanwhile, Definium Therapeutics notched another late-stage trial win for its LSD drug, and Novartis continues to reel from the company's triple asset stumble.

https://missionprephealthcare.com/mental-health-resources/attachment-styles/dismissive-avoidant-vs-fearful-avoidant/Roughly a quarter of adults are dismissive avoidant, but their path to healing looks nothing like a fearful avoidant's. Experts break down why identical therapy tactics can backfire - and what actually rebuilds trust, one small step at a time. Mission Prep City: San Juan Capistrano Address: 30310 Rancho Viejo Rd. Website: https://missionprephealthcare.com/

Send us Fan MailIs the newborn vitamin K shot really being skipped more often these days, and does that actually matter clinically? This week on Journal Club, Ben and Daphna review a nationwide Swedish cohort study of over two million births, published in JAMA Pediatrics, examining trends in non-receipt of intramuscular vitamin K and its link to bleeding in infancy. Non-receipt nearly doubled between 2006 and 2021, and infants without intramuscular vitamin K had significantly higher odds of bleeding, including intracranial bleeding, than those who received it — oral vitamin K carried an even higher bleeding risk still. Ben and Daphna also discuss home birth data, families requesting oral alternatives, and how best to counsel parents navigating a vitamin K refusal in clinic today.----Vitamin K Prophylaxis in Newborns and Bleeding in Infancy. Simatou E, Tsamantioti E, Hallström A, Stephansson O, Razaz N, Persson M, Bolk J.JAMA Pediatr. 2026 Sep 1;180(9):995-1004. doi: 10.1001/jamapediatrics.2026.2606.PMID: 42440325Support the showAs always, feel free to send us questions, comments, or suggestions to our email: nicupodcast@gmail.com. You can also contact the show through Instagram or Twitter, @nicupodcast. Or contact Ben and Daphna directly via their Twitter profiles: @drnicu and @doctordaphnamd. The papers discussed in today's episode are listed and timestamped on the webpage linked below.Enjoy!

Send us Fan MailDo we really need a DAT on every baby born to a group O or Rh-negative mother? This week on Journal Club, Ben and Daphna dig into a new Pediatrics study questioning routine Direct Antiglobulin Testing (DAT) in low-risk neonates with ABO or RhD incompatibility. Using data from over 1,300 infants, the authors found that transcutaneous bilirubin alone predicted the need for phototherapy just as well as DAT in ABO-incompatible babies, and that passive anti-D from RhoGAM rarely caused significant hemolysis in RhD-incompatible infants. Ben and Daphna also discuss what this means for institutions running DAT on every newborn, how to tell passive anti-D apart from true alloimmunization, and why a more targeted approach to bilirubin screening may be overdue.----Utility of DAT in Low-Risk Neonates With ABO or RhD Incompatibility. Tsai TL, Ma T, Nester T.Pediatrics. 2026 Sep 1;158(3):e2026076989. doi: 10.1542/peds.2026-076989.PMID: 42642037Support the showAs always, feel free to send us questions, comments, or suggestions to our email: nicupodcast@gmail.com. You can also contact the show through Instagram or Twitter, @nicupodcast. Or contact Ben and Daphna directly via their Twitter profiles: @drnicu and @doctordaphnamd. The papers discussed in today's episode are listed and timestamped on the webpage linked below.Enjoy!

Send us Fan MailIn this episode of From the Heart, Drs. Nim Goldshtrom and Adrianne Bischoff talk with Dr. Kristin Elgersma, a nurse-researcher whose path into neonatal nutrition began at her son's bedside in a cardiac ICU. A former concert pianist turned nurse-researcher, Kristin asked a question no one had: does human milk change outcomes for babies with congenital heart disease? Her multicenter PC4 study of day-by-day data from over 800 infants across 25 centers found no link between human milk and NEC, though bovine-derived formula or fortifier tripled NEC risk within five days, while higher human milk intake meant roughly nine fewer hospital days. They cover lactation support, donor milk gaps between NICUs and CICUs, and practical next steps.----Elgersma et al. Human milk feeding, fortification initiation, and clinical outcomes in neonates with critical congenital heart disease: A multi-institutional study. medRxiv 2026. DOI 10.64898/2026.08.20.26360934 (preprint, no PMID)Elgersma et al. Human milk feeding and direct breastfeeding improve outcomes for infants with single ventricle congenital heart disease: Propensity score-matched analysis of the NPC-QIC registry. J Am Heart Assoc 2023. PMID 37642030Support the showAs always, feel free to send us questions, comments, or suggestions to our email: nicupodcast@gmail.com. You can also contact the show through Instagram or Twitter, @nicupodcast. Or contact Ben and Daphna directly via their Twitter profiles: @drnicu and @doctordaphnamd. The papers discussed in today's episode are listed and timestamped on the webpage linked below.Enjoy!

Send us Fan MailIn this episode of From the Heart, Dr. Nim Goldshtrom and Dr. Adrianne Bischoff dissect a hemodynamics consult that changes shape twice in 48 hours. A 30-week recipient twin from twin-to-twin transfusion syndrome presents with biventricular dysfunction and suprasystemic pulmonary hypertension, starts on epinephrine and milrinone, and stabilizes. Then overnight, everything falls apart: hypotension, rising lactate, falling urine output. Only on repeat echo does the real diagnosis emerge: hypertrophic obstructive cardiomyopathy (HOCM) with dynamic left ventricular outflow tract obstruction, where the "correct" initial therapy becomes dangerous. Nim and Adrianne unpack why milrinone can worsen outflow obstruction, why vasopressin beats dobutamine, and when esmolol helps or harms. It's a masterclass in resisting anchoring bias and treating evolving physiology, not just numbers. Support the showAs always, feel free to send us questions, comments, or suggestions to our email: nicupodcast@gmail.com. You can also contact the show through Instagram or Twitter, @nicupodcast. Or contact Ben and Daphna directly via their Twitter profiles: @drnicu and @doctordaphnamd. The papers discussed in today's episode are listed and timestamped on the webpage linked below.Enjoy!

Paul Romness, CEO, President, and Chair of OS Therapies, which is developing an immunotherapy to treat osteosarcoma, a rare bone cancer that stimulates the immune system to identify and eliminate cancer cells. The approach upregulates positive immune factors amd downregulates negative factors resulting in a dual biomarker response and better management of side effects. OS Therapies plans to expand its platform technology to other solid tumors with significant unmet needs, including breast,  esophageal, and colorectal cancer.    Paul explains, "What I think is important is that OS Therapies was started for unmet need, not just in the United States, but there are 20,000 patients a year that get osteosarcoma globally. And it's our responsibility to address patients globally. And it is interesting from a regulatory standpoint, as they start to coordinate with each other, that there are routes for us to get approval in the United States through MHRA, through the UK, and through the collaboration with the EU, with a system called Orbis. But we're also still very confident and very encouraged by the progress we've made with the FDA over the last few months."   "And for OS Therapies, we will pivot to other solid tumors. So our primary mission is osteosarcoma, but once we get approval, we'll pivot to other solid tumors that still have a lot of unmet medical need, like breast cancer. There are still 40,000, mostly women, dying each year of breast cancer, esophageal cancer, or colorectal cancer. So if we can encourage other companies to come into this space, we'll not only achieve our primary mission, but we'll also deliver for patients, which is our goal." #OSTherapies #Osteosarcoma #RareDisease #RareCancer #PediatricOncology #RareDiseaseOncology #SolidTumors #Immunotherapy #ListeriaCancerImmunotherapy #Biomarkers #Oncology #ClinicalTrials #HER2 #CancerResearch #ComparativeOncology#CanineOsteosarcoma ostherapies.com Listen to the podcast here

Paul Romness, CEO, President, and Chair of OS Therapies, which is developing an immunotherapy to treat osteosarcoma, a rare bone cancer that stimulates the immune system to identify and eliminate cancer cells. The approach upregulates positive immune factors amd downregulates negative factors resulting in a dual biomarker response and better management of side effects. OS Therapies plans to expand its platform technology to other solid tumors with significant unmet needs, including breast,  esophageal, and colorectal cancer.    Paul explains, "What I think is important is that OS Therapies was started for unmet need, not just in the United States, but there are 20,000 patients a year that get osteosarcoma globally. And it's our responsibility to address patients globally. And it is interesting from a regulatory standpoint, as they start to coordinate with each other, that there are routes for us to get approval in the United States through MHRA, through the UK, and through the collaboration with the EU, with a system called Orbis. But we're also still very confident and very encouraged by the progress we've made with the FDA over the last few months."   "And for OS Therapies, we will pivot to other solid tumors. So our primary mission is osteosarcoma, but once we get approval, we'll pivot to other solid tumors that still have a lot of unmet medical need, like breast cancer. There are still 40,000, mostly women, dying each year of breast cancer, esophageal cancer, or colorectal cancer. So if we can encourage other companies to come into this space, we'll not only achieve our primary mission, but we'll also deliver for patients, which is our goal." #OSTherapies #Osteosarcoma #RareDisease #RareCancer #PediatricOncology #RareDiseaseOncology #SolidTumors #Immunotherapy #ListeriaCancerImmunotherapy #Biomarkers #Oncology #ClinicalTrials #HER2 #CancerResearch #ComparativeOncology#CanineOsteosarcoma ostherapies.com Download the transcript here

How Current Health Improves Access to Advanced Therapies Chris McGhee, CEO & Co-Founder of Current Health, returns to share how the national dialogue about health at home programs, drug therapies, and empowered consumers has changed since he reacquired his company from Best Buy Health.  All that, plus the Flava of the Week about the launch of the CMS ACCESS Model. Is CMS creating a framework for treating chronic conditions rather than just a short-term payment structure, and how does the model open up new partnerships that can help make preventive health a reality? Find all of our network podcasts on your favorite podcast platforms and be sure to subscribe and like us. Learn more at www.healthcarenowradio.com/listen/

Dr. Jared Rutter, PhD, Professor of Biochemistry at the University of Utah and Howard Hughes Medical Institute Investigator, is a leading expert on mitochondria and metabolism. He explains how mitochondria produce the energy for your cells to work but also how they regulate cell growth and replication and thereby contribute to health and disease. We also discuss how mitochondria are linked to aging, cancer, and other diseases. Our conversation explores your metabolism as the composite of trillions of individual cells and points to new ways to improve health, avoid, and treat diseases. Show notes: https://go.hubermanlab.com/297-jared-rutter Pre-order Protocols: https://protocolsbook.com Thank you to our sponsors AG1: https://drinkag1.com/huberman Joovv: https://joovv.com/huberman BetterHelp: https://betterhelp.com/huberman Eight Sleep: https://eightsleep.com/huberman Function: https://functionhealth.com/huberman Timestamps (00:00:00) Jared Rutter (00:02:29) Metabolism, Cells; Aging (00:08:36) Mitochondria, Origin & Cell Complexity (00:13:07) Sponsors: Joovv & BetterHelp (00:15:16) Mitochondria Genome, Inheritance (00:18:18) Mitochondria & Spatial Distribution; Cell-Specific Metabolism (00:25:59) Nutrient Energy, Hormones, Fat Cells (00:31:13) Glucose, ATP Conversion, Pyruvate (00:36:41) Cell Choice: Energy or Growth, Cancer; Virus (00:46:02) Sponsors: AG1 & Eight Sleep (00:48:36) Microbiome, Role of Humans (00:51:44) Molecule Discovery Process, MPC1, MPC2 (00:59:42) Cell Resource Sensing, Fasting, Glucagon, Fat Cells; Neurons, Heart (01:07:03) Cell Resource Allocation, MPC, Heart Failure; Disease (01:11:46) Sponsor: Function (01:13:24) Cell Size vs Fuel Balance, Cell Identity & Disease (01:20:43) MPC Discovery, Genetics, Model Systems (01:24:29) Lactate, Oxygen, Exercise; Energy Prioritization Hierarchy (01:31:32) Cancer, Mutations, Metabolism Changes & Warburg Effect (01:36:18) Cancer Challenges & Therapies (01:43:00) Therapy Combinations, Unique Cancer Mutations & Metabolism (01:48:31) Technology to Visualize Metabolism; Disease, Metabolism & Scents (01:56:34) Excess Energy & Mitochondria, Reactive Oxygen Species (02:01:12) Zero-Cost Support, YouTube, Spotify & Apple Follow, Reviews & Feedback, Sponsors, Protocols Book, Social Media, Neural Network Newsletter Disclaimer & Disclosures Learn more about your ad choices. Visit megaphone.fm/adchoices

Send us Fan MailDisclosure: Dr. Wanda Barfield appeared on this episode in her personal capacity. The views she expresses are her own and do not represent the official positions of the Centers for Disease Control and Prevention, the Department of Health and Human Services, or the United States government.The American Academy of Pediatrics has never had a neonatologist as president. This September, that could change. In this special episode, Ben sits down with Dr. Wanda Barfield, neonatologist, retired Rear Admiral and Assistant Surgeon General in the US Public Health Service, and longtime director of the CDC's Division of Reproductive Health, to hear what she would bring to the role. She lays out her three priorities, supporting pediatricians, protecting access, and leading with science and equity, and addresses the questions our field is wrestling with right now: training, staffing, the erosion of trust in science, and whether neonatology should go it alone. Her answer is that we are stronger together, and that having a neonatologist at the helm of the AAP would give our specialty a voice it has never had. Voting is open to AAP members through September 16. Meet the candidate, then go vote. Support the showAs always, feel free to send us questions, comments, or suggestions to our email: nicupodcast@gmail.com. You can also contact the show through Instagram or Twitter, @nicupodcast. Or contact Ben and Daphna directly via their Twitter profiles: @drnicu and @doctordaphnamd. The papers discussed in today's episode are listed and timestamped on the webpage linked below.Enjoy!

Send us Fan MailThis week's Journal Club. Monday, nasal CPAP versus NIPPV as the bridge to minimally invasive surfactant in infants born before 30 weeks, first author Dr. Hui Zhang. Tuesday, the PAEAN trial on high-dose erythropoietin for neonatal HIE, led by Dr. Helen Liley. Wednesday, extended infusion versus bolus feeding for weight gain in extremely-low-birth-weight infants, from Dr. Haribalakrishna Balasubramanian's team in India. Thursday, the DROP-ROP trial, testing dexamethasone eye drops against treatment-requiring ROP, led by Dr. Ann Hellström. Friday, Neo News: Eli and Ben on The Pitt's viral boundary-setting scene and what it says about burnout in medicine.----Nasal Continuous Positive Airway Pressure vs Nasal Intermittent Positive Pressure Ventilation in Preterm Infants With Respiratory Distress Syndrome: A Randomized Clinical Trial. Zhang H, Zhang Y, Zeng L, Tong X, Piao M, He H, Zhao C, Xie H, Zheng Z, Cui Q, Lai Y, Wang H, Wang L, Liu H, Tian X, Wu H, Kang L, Han T.JAMA Netw Open. 2026 Jun 1;9(6):e2619785. doi: 10.1001/jamanetworkopen.2026.19785.Erythropoietin for Neonatal Hypoxic-Ischemic Encephalopathy: A Randomized Clinical Trial. Liley HG, Hunt RW, O'Connell RL, Battin MR, Novak I, Wu YW, Ballard R, Askie L, Badawi N, Ghadge A, Jacobs SE, Juul SE, Sebastian L, Wagh D, Simes RJ; PAEAN Study Investigators.JAMA Pediatr. 2026 Jul 27:e263082. doi: 10.1001/jamapediatrics.2026.3082. Online ahead of print.Effect of Extended Infusion Versus Intermittent Bolus Feedings on Hospital Weight Gain in Extremely Low Birth Weight Infants Born at

Send us Fan MailA medical student on The Pitt finishes her shift, is asked to stay, and tells her supervisor to learn some boundaries. The internet did not let it go. Ben and Eli use that moment to work through what boundary setting actually looks like in a NICU, why a tired clinician makes different decisions at three in the morning than at three in the afternoon, and where duty hours collide with the fact that patients do not arrive on a curriculum. Also, why handing a resident your pager at two PM may be the cheapest patient safety intervention available.----Haridasani Gupta A. On "The Pitt," She Clocked Out on Time. In Real Life, It Started a Debate. The New York Times. May 11, 2026. https://www.nytimes.com/2026/05/11/style/the-pitt-joy-kwon-irene-choi-work-life-balance.htmlSupport the showAs always, feel free to send us questions, comments, or suggestions to our email: nicupodcast@gmail.com. You can also contact the show through Instagram or Twitter, @nicupodcast. Or contact Ben and Daphna directly via their Twitter profiles: @drnicu and @doctordaphnamd. The papers discussed in today's episode are listed and timestamped on the webpage linked below.Enjoy!

Welcome back to the Oncology Brothers podcast! In this episode, we were joined by the MPN specialists Drs. Brandi Reeves and Naveen Pemmaraju, to discuss the treatment options for polycythemia vera (PV) and essential thrombocythemia (ET).   We dived deep into the side effect profiles and management strategies for key treatments, including: Hydroxyurea: Learnt about dosing strategies, monitoring, and the importance of managing acute and chronic side effects such as leg ulcers and skin cancer risks Ropeginterferon alfa-2b: Discover the benefits and potential side effects, including flu-like symptoms and neuropsychiatric issues, and how to approach dosing for patients with pre-existing conditions Ruxolitinib: Understand the common side effects, including myelosuppression and weight gain, and the critical importance of tapering off the medication rather than stopping abruptly Rusfertide: Get insights into this new hepcidin mimetic and its promising role in managing PV, along with potential side effects to monitor   Join us for a comprehensive tox check discussion that aims to equip healthcare professionals with clinical pearls for managing these treatments effectively.   Listen us on: Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o    Follow us on social media: X/Twitter: ⁠https://x.com/oncbrothers⁠  ⁠Instagram: ⁠https://www.instagram.com/oncbrothers⁠  Website: ⁠https://oncbrothers.com/⁠    Subscribe for more insights and updates from the Oncology Brothers! #PolycythemiaVera, #MPN, #EssentialThrombocythemia, #CytotoxicTherapies, #OncologyBrothers  

Send us Fan MailSteroids again? This time in the eye. Daphna brings the DROP-ROP trial from JAMA Pediatrics, a double-masked randomized study across fourteen Swedish centers asking whether topical dexamethasone can stop pre-threshold ROP from progressing to type one disease. One hundred infants, born under 30 weeks, dosed for up to twelve weeks, some still getting drops at home. Twenty percent needed laser or anti-VEGF in the dexamethasone arm versus thirty-eight percent on placebo, a relative risk reduction that did not reach significance. Ben and Daphna talk through the safety signals, the intraocular pressure question, and how fast our field adopts promising ROP data.----Dexamethasone Eye Drops to Prevent Treatment-Requiring Retinopathy of Prematurity: The DROPROP Randomized Clinical Trial. Hellström A, Petrishka-Lozenska M, Sjöbom U, Wallander J, Nilsson AK, Löfqvist C, Ley D, Gränse L, Öhnell HM, Hård AL, Jakobsson G, Sävman K, Domellöf M, Löfgren S, Larsson E, Smith LEH, Pivodic A, Lundgren P; DROPROP Collaboration Group.JAMA Pediatr. 2026 Aug 3:e263247. doi: 10.1001/jamapediatrics.2026.3247. Online ahead of print.Support the showAs always, feel free to send us questions, comments, or suggestions to our email: nicupodcast@gmail.com. You can also contact the show through Instagram or Twitter, @nicupodcast. Or contact Ben and Daphna directly via their Twitter profiles: @drnicu and @doctordaphnamd. The papers discussed in today's episode are listed and timestamped on the webpage linked below.Enjoy!

Send us Fan MailEvery unit has a bolus camp and a continuous camp, and both are usually dug in. Ben brings a single center non-inferiority trial from India, published in the Journal of Pediatrics, randomizing 132 infants born before 29 weeks and under a thousand grams to extended infusion feeding or two hourly bolus feeds. Weight gain at discharge was essentially identical at 15.3 versus 15.7 grams per kilo per day, but the infusion group lost two fewer days to interrupted feeds. Ben and Daphna talk through the five on one off infusion cycle, two hourly bolus feeding, and why fewer interruptions may be the real outcome.----Effect of Extended Infusion Versus Intermittent Bolus Feedings on Hospital Weight Gain in Extremely Low Birth Weight Infants Born at

The promise of precision medicine depends on more than scientific innovation. It also depends on whether eligible patients can be identified, tested and connected to the most appropriate treatment. In this episode of The Top Line, host Kelly Hogan is joined by Susanne Munksted, chief growth officer at Diaceutics, and Jordan Clark, chief customer officer, to discuss why many diagnostic-driven therapies still fail to reach their full potential. Drawing on findings from Diaceutics' practice gap studies, the conversation explores where patients are being lost across the diagnostic pathway and why improvements in testing have not always translated into better treatment decisions. The guests discuss increasing healthcare complexity, expanding biomarker requirements and the challenges clinicians face when making treatment decisions under time pressure.See omnystudio.com/listener for privacy information.

Send us Fan MailWe already had HEAL, so why run this trial at all? Daphna brings PAEAN from JAMA Pediatrics, a phase three trial across 24 units in Australia, New Zealand, and Singapore that gave high dose erythropoietin to 313 late preterm and term infants already receiving therapeutic hypothermia for HIE. Same drug, same dosing, nearly the same eligibility criteria as HEAL, by design. Death or moderate to severe developmental deficit at two years was 34 percent with EPO versus 29 percent with placebo. Ben and Daphna talk through the thrombosis signal, why replication feels so foreign in neonatology, and what is left in the adjunct pipeline.----Erythropoietin for Neonatal Hypoxic-Ischemic Encephalopathy: A Randomized Clinical Trial. Liley HG, Hunt RW, O'Connell RL, Battin MR, Novak I, Wu YW, Ballard R, Askie L, Badawi N, Ghadge A, Jacobs SE, Juul SE, Sebastian L, Wagh D, Simes RJ; PAEAN Study Investigators.JAMA Pediatr. 2026 Jul 27:e263082. doi: 10.1001/jamapediatrics.2026.3082. Online ahead of print.Support the showAs always, feel free to send us questions, comments, or suggestions to our email: nicupodcast@gmail.com. You can also contact the show through Instagram or Twitter, @nicupodcast. Or contact Ben and Daphna directly via their Twitter profiles: @drnicu and @doctordaphnamd. The papers discussed in today's episode are listed and timestamped on the webpage linked below.Enjoy!

Send us Fan MailMost trials comparing CPAP and NIMV leave a lingering doubt about whether surfactant explained the difference. This one does not. Ben brings a multicenter noninferiority trial from JAMA Network Open in infants born between 24 and 29 weeks, randomized to nasal CPAP or NIMV with every baby receiving less invasive surfactant administration. The trial stopped early for futility after 312 infants. Noninvasive ventilation failure within 72 hours was 26 percent on CPAP versus 13 percent on NIMV. Ben and Daphna talk through what happens when surfactant is off the table, the unexpected NEC signal, and where the guidelines may need revisiting.----Nasal Continuous Positive Airway Pressure vs Nasal Intermittent Positive Pressure Ventilation in Preterm Infants With Respiratory Distress Syndrome: A Randomized Clinical Trial. Zhang H, Zhang Y, Zeng L, Tong X, Piao M, He H, Zhao C, Xie H, Zheng Z, Cui Q, Lai Y, Wang H, Wang L, Liu H, Tian X, Wu H, Kang L, Han T.JAMA Netw Open. 2026 Jun 1;9(6):e2619785. doi: 10.1001/jamanetworkopen.2026.19785.Support the showAs always, feel free to send us questions, comments, or suggestions to our email: nicupodcast@gmail.com. You can also contact the show through Instagram or Twitter, @nicupodcast. Or contact Ben and Daphna directly via their Twitter profiles: @drnicu and @doctordaphnamd. The papers discussed in today's episode are listed and timestamped on the webpage linked below.Enjoy!

Dr. Kyla Ortved helps horse owners understand joint therapies in senior horses. She is an Associate Professor of Large Animal Surgery at the University of Pennsylvania's New Bolton Center. Dr. Ortved is boarded in Surgery and Veterinary Sports Medicine & Rehabilitation.My Senior Horse - Episode 52 Guests and Links:Guests: Dr. Kyla Ortved, Associate Professor of Large Animal Surgery at the University of Pennsylvania's New Bolton CenterConnect with Host: Kimberly S. Brown of Editorial Director of My Senior Horse | Email Kim (kbrown@equinenetwork.com) | Follow Kim on LinkedIn (@kimberlylsbrown)

View the Show Notes Page for This Episode Become a Member to Receive Exclusive Content Sign Up to Receive Peter's Weekly Newsletter In this episode, Peter sits down with Dr. Linus Abrams, a psychiatrist with nearly 35 years of clinical experience specializing in mood disorders and psychopharmacology, to explore how our understanding of mental health is evolving beyond the traditional neurotransmitter model. After decades in practice, Linus began questioning many of the assumptions underlying modern psychiatry, leading him to investigate how hormones, metabolism, inflammation, circadian biology, and the endocrine system shape mood and cognition. Together, Peter and Linus examine why psychiatric care should aim not only to reduce symptoms but also to restore the full human experience. They discuss how psychiatric medications work, where they fall short, and why distinguishing bipolar disorder from unipolar depression is essential for effective treatment. The conversation also explores the growing mental health burden of social isolationn associated with digital devices and social media, along with the biological factors—nutrition, exercise, sleep, and chronic stress—that influence resilience and distress tolerance. Linus explains the powerful roles of estrogen, progesterone, testosterone, and thyroid hormone in regulating mood and cognition across the lifespan. Finally, Peter and Linus review the promise and limitations of ketamine and psychedelic therapies, and why the future of psychiatry may lie in integrating neuroscience, endocrinology, and whole-body physiology to better understand, diagnose, and treat mental illness. We discuss: Linus's passion for understanding his patients and going beyond traditional psychiatry [2:45]; A short primer on the different classes of drugs used in psychiatry [12:45]; Evaluation of a patient with bipolar disorder [26:00]; An evolutionary perspective on depression [33:30]; Changes in the modern world triggering mental health problems [41:00]; An evolutionary perspective on insomnia [48:15]; Peter's window analogy to understand distress tolerance and irritability [49:45]; The impact of foundational biological factors on psychiatry: nutrition, exercise, sleep, and endocrinology [52:30]; The effect of estradiol on neurotransmitters in the brain [58:15]; Options for increasing testosterone in men, and why clomiphene is inferior to exogenous testosterone [1:11:00]; The rapid drop in progesterone is linked to both premenstrual dysphoric disorder (PMDD) and postpartum depression [1:14:30]; Treatment of postpartum depression [1:18:00]; Hypothyroidism presenting as depression: how Linus makes the diagnosis and what he uses for treatment [1:26:00]; The link between hyperarousal and chronically elevated cortisol [1:39:30]; A case where the menopause transition uncovers bipolar disorder [1:44:15]; Ketamine as a tool to treat recalcitrant depression, and concerns about its recreational use [1:49:15]; Case study: an Alzheimer's patient who improved after psilocybin, and why Linus is cautious about drawing conclusions from it [1:55:15]; Peter's experience with psychedelics, and the myth that estrogen is bad for men [2:00:30]; The therapeutic potential of psychedelics in psychiatry [2:11:00]; and More. Connect With Peter on Twitter, Instagram, Facebook and YouTube